Companies › EpicentRx
2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AdAPT-001 Oncolytic virus | – | Phase 2 | Solid Tumor, Adult | Dec 2026 |
| RRx-001 unclear - likely prodrug or small molecule with cytoprotective properties | – | Phase 2 | Oral Mucositis | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04673942 | AdAPT-001 | Phase 2 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT05966194 | RRx-001 | Phase 2 | Oral Mucositis | Oncology | Jul 2027 |
No annotated target.
–
Elpiscience (Suzhou) Biopharma Ryvu Therapeutics Criterium Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.